» Articles » PMID: 17942622

Differential Modulation by Nicotine of Substantia Nigra Versus Ventral Tegmental Area Dopamine Neurons

Overview
Journal J Neurophysiol
Specialties Neurology
Physiology
Date 2007 Oct 19
PMID 17942622
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Midbrain dopamine (DA) neurons are found in two nuclei, the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). The SNc dopaminergic projections to the dorsal striatum are involved in voluntary movement and habit learning, whereas the VTA projections to the ventral striatum contribute to reward and motivation. Nicotine induces profound DA release from VTA dopamine neurons but substantially less from the SNc. Nicotinic acetylcholine receptor (nAChR) expression differs between these nuclei, but it is unknown whether there are differences in nAChR expression on the afferent projections to these nuclei. Here we have compared the nicotinic modulation of excitatory and inhibitory synaptic inputs to VTA and SNc dopamine neurons. Although nicotine enhances both the excitatory and inhibitory drive to SNc DA cells with response magnitudes similar to those seen in the VTA, the prevalence of these responses in SNc is much lower. We also found that a mixture of nAChR subtypes underlies the synaptic modulation in SNc, further distinguishing this nucleus from the VTA, where alpha7 nAChRs enhance glutamate inputs and non-alpha7 receptors enhance GABA inputs. Finally, we compared the nicotine sensitivity of DA neurons in these two nuclei and found larger response magnitudes in VTA relative to SNc. Thus the observed differences in nicotine-induced DA release from VTA and SNc are likely due to differences in nAChR expression on the afferent inputs as well as on the DA neurons themselves. This may explain why nicotine has a greater effect on behaviors associated with the VTA than the SNc.

Citing Articles

A Brief Overview of the Neuropharmacology of Opioid Addiction.

Grothusen J, Blendy J, Barr G Transl Perioper Pain Med. 2023; 9(4):491-496.

PMID: 36935906 PMC: 10019698. DOI: 10.31480/2330-4871/165.


What Do Randomized Controlled Trials Inform Us About Potential Disease-Modifying Strategies for Parkinson's Disease?.

Ong W, Leow D, Herr D, Yeo C Neuromolecular Med. 2022; 25(1):1-13.

PMID: 35776238 DOI: 10.1007/s12017-022-08718-x.


Specificity of Varenicline in Blocking Mesolimbic Circuit Activation to Natural and Drug Rewards.

Goldstein N, Carty J, Betley J Neuroscience. 2021; 483:40-51.

PMID: 34923039 PMC: 8837713. DOI: 10.1016/j.neuroscience.2021.12.016.


An electrophysiological perspective on Parkinson's disease: symptomatic pathogenesis and therapeutic approaches.

Lee L, Huang C, Chuang H, Lai H, Yang C, Yang Y J Biomed Sci. 2021; 28(1):85.

PMID: 34886870 PMC: 8656091. DOI: 10.1186/s12929-021-00781-z.


Dopamine Circuit Mechanisms of Addiction-Like Behaviors.

Poisson C, Engel L, Saunders B Front Neural Circuits. 2021; 15:752420.

PMID: 34858143 PMC: 8631198. DOI: 10.3389/fncir.2021.752420.